Success Story
Ashbrook Holdings Limited has taken a major step forward in its buy-and-build strategy with the acquisition of Webb Injection Moulders, supported by a £2m funding package structured by Arbuthnot Commercial Asset Based Lending and backed by the British Business Bank’s Growth Guarantee Scheme.
| Region/Nation | South East |
|---|---|
| Sector | Manufacturing |
| Programme | Growth Guarantee Scheme |
| Partner |
The funding enabled the strategic acquisition and laid the foundation for future growth across the precision moulding sector.
Ashbrook Group’s latest acquisition brings together two highly specialised businesses, Webb Injection Moulders and Cranfield Solutions, each known for technical excellence in injection moulding.
With a clear vision to build a geographically diverse group of complementary manufacturing businesses, the Group’s growth journey has been powered by a responsive, partnership-driven funding solution from Arbuthnot Commercial Asset Based Lending.
Webb Injection Moulders, based in Biggleswade, is a well-established injection moulding business serving markets including automotive, with services ranging from design consultation to just-in-time delivery.
Cranfield Solutions, founded in 2003 and based in Milton Keynes, focuses on complex, high-performance materials and in-house toolmaking.
Both businesses uphold a strong family-business ethos, where employee engagement and shared expertise drive innovation.
Recognising the potential for synergies and growth, Ashbrook Holdings sought to unite these two businesses under a single, scalable group, investing in complementary capabilities and operational excellence.
Finance for acquisition
To facilitate the acquisition of Webb Injection Moulders, Arbuthnot Commercial Asset Based Lending delivered a tailored £2m funding package comprising an Invoice Discounting facility and a Growth Guarantee Scheme loan for Webb, alongside an invoice discounting line for Cranfield Solutions.
This structure provided immediate transactional support while offering long-term flexibility for continued growth.
Crucially, the finance solution aligned with Ashbrook’s long-term vision of building a sustainable, geographically spread group of high-quality manufacturers operating across adjacent sectors.
The beautiful thing about Arbuthnot Commercial ABL is they think about the deal and genuinely want to get it done. You can have an honest conversation, tell them the facts, and get open communication in return. - Leon Edwards Executive Chairman, Ashbrook Holdings
Partnership in action
What set this transaction apart was the strategic fit of the acquisition, and the seamless working relationship between the funder and the business.
This transaction brings together two complementary businesses and highlights the speed, flexibility and certainty we bring to our clients. We’re excited to support Ashbrook Group as they scale through future acquisitions. - Andrew Rutherford Commercial Director, Arbuthnot Commercial Asset Based Lending
Accelerating growth with confidence
With a committed funding partner and a clear acquisition roadmap, Ashbrook Group is well-positioned to scale across adjacent sectors such as joinery and metal fabrication, building a resilient, innovative group rooted in quality, shared skills and long-term relationships.
The Growth Guarantee Scheme is here to help ambitious UK businesses like Ashbrook Holdings realise their strategic goals. By supporting acquisitions that strengthen UK manufacturing, the scheme plays a vital role in enabling long-term growth, innovation, and sector resilience. - Sean Hutchinson British Business Bank
Tags related to this content:
More success stories
Read a success story about Ember Transport
With support from Triodos Bank, Ember secured a £490,000 loan through the government’s Recovery Loan Scheme, which has since been relaunched as the Growth Guarantee Scheme enabled the fleet to grow to 38 vehicles, supported by Ember’s proprietary tech platform, EmberOS.
Read a success story about Magnitude Biosciences
Magnitude Biosciences, a specialist contract research organisation (CRO) in County Durham offering in vivo discovery of treatments for age-related conditions and other diseases using C. elegans, secured over £706,000 in combined funding to scale up its high-throughput screening (HTS) platform
Read a success story about Synergy Health
Synergy Health received a five-figure investment from NPIF II – River Capital & GC Business Finance Smaller Loans, which is managed by the consortium as part of the Northern Powerhouse Investment Fund II.